Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease

Science. 2001 Aug 10;293(5532):1164-6. doi: 10.1126/science.1060937.

Abstract

The power of placebos has long been recognized for improving numerous medical conditions such as Parkinson's disease (PD). Little is known, however, about the mechanism underlying the placebo effect. Using the ability of endogenous dopamine to compete for [11C]raclopride binding as measured by positron emission tomography, we provide in vivo evidence for substantial release of endogenous dopamine in the striatum of PD patients in response to placebo. Our findings indicate that the placebo effect in PD is powerful and is mediated through activation of the damaged nigrostriatal dopamine system.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antiparkinson Agents / administration & dosage
  • Antiparkinson Agents / therapeutic use*
  • Apomorphine / administration & dosage
  • Apomorphine / therapeutic use*
  • Corpus Striatum / diagnostic imaging
  • Corpus Striatum / metabolism*
  • Dopamine / metabolism*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism
  • Placebo Effect*
  • Placebos / administration & dosage
  • Raclopride / metabolism
  • Synapses / metabolism
  • Tomography, Emission-Computed

Substances

  • Antiparkinson Agents
  • Placebos
  • Raclopride
  • Apomorphine
  • Dopamine